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Abstract: In the 1970s, morphological evidence collected by electron microscopy linked 
mineral deposition (“calcification” or “mineralization”) in newly-forming bone to 
membrane-encapsulated particles of a diameter of approximately 100 nm (50–200 nm) that 
were called “matrix vesiscles”. As the characterisation of these vesicles progressed 
towards their biochemical composition, the role of lipids in the biomineralization process 
appeared to be crucial. In particular, a group of cell-membrane phospholipids were 
identified as major players in the crystal formation process. Indeed, in the 1980s it became 
clear that phosphatidylserine, together with proteins of the annexin family, was among the 
most important molecules in binding calcium ions and that this phospholipid was involved 
in the regulation of the early stages of mineralization in vivo. During the same period of 
time, the number of surgical implantations of orthopaedic, dental and maxilo-facial devices 
requiring full integration with the treated bone prompted the study of new functionalisation 
molecules able to establish a stable bonding with the mineral phase of the host tissue. In 
the late 1990s studies started that aimed at exploiting the potential of calcium-binding 
phospholipids and, in particular, of the phosphatidylserine as functionalisation molecules 
to improve the osteointegration of artificial implants. Later, papers have been published 
that show the potential of the phophatidylserine and phosphatidylserine-mimicking coating 
technology to promote calcification both in vitro and in vivo. The promising results support 
the future clinical application of these novel osteointegrative biomaterials. 
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1. Bone structure and function 
Bone plays fundamental mechanical and protective functions in vertebrates. These functions are 
successfully exerted by the unique combination of a mineral phase deposited on a proteic template. 
Ossification is the formation of bone by the activity of cells termed “osteoblasts” which deposit the 
proteinaceous matrix (the osteoid tissue) and later promote the deposition of minerals which they take 
from the blood. This process of mineral deposition is called “mineralization”. Alternatively, the 
process is also indicated as “calcification” to emphasise the calcium-based composition of the mineral 
phase [1]. However, osteoblasts are not the sole cell type responsible for the mineralization process: 
“chondrocytes” (the cells of the cartilage) are able to promote the “endochondral ossification” [2] and 
“odontoblasts” (the cells of the teeth) produce mineralized dentin [3]. 
As any other tissue of the vertebrate and human body, bone is a living tissue that undergoes a 
continuous remodelling process where the older bone is continuously resorbed by the activity of some 
cells, the so called “osteoclasts”, and gradually replaced by newly-formed tissue deposited by bone 
producing cells. “Bone turn-over” is the term which defines this continuous cycle of bone resorption 
and apposition which is driven by these types of cells. Bone turn-over is finely tuned by biochemical 
signaling (hormonal, autocrine and paracrine) and is the result of a complex series of biochemical and 
cellular interactions. These events contradict the apparently inert nature of the bony tissue. Indeed, the 
annual rate of bone turn-over in a healthy individual ranges from 10% to 20% percent of the whole 
skeleton [1]. 
Alongside the biochemical signaling, bone is deposited in proportion to the compressive cyclic load 
that the tissue has to sustain. A microscopic analysis shows that bone deposition follows the lines of 
mechanical stress. Therefore, each bone segment constantly adapts its inner structure to the applied 
loads, a process termed “Bone Remodelling” [1,4–6]; this phenomenon can be easily seen at work also 
during the fracture healing process [7–9] or during bone regeneration by limb lengthening  
techniques [10–11].  
The organic matrix of bone is composed primarily of collagen, a fibre-arranged protein that 
provides flexibility to the tissue. Collagen accounts for approximately 10% by weight of the adult bone 
mass. Bone is mainly composed of a mineral phase made of carbonated hydroxyapatite (about 65% of 
adult bone mass). Water comprises approximately 25% of adult bone mass. Collagen fibers have great 
tensile strength while the calcium phosphate phase offers compressive strength. These properties are 
enhanced by the intimate bonding of the organic and mineral phase to provide the unique tensile and 
compressive properties of the bony tissues [1,12]. 
2. Matrix Vesicles 
In 1969, following an electron microscope investigation, Anderson reported the presence of “matrix 
vesiscles” (MVs) associated with the process of bone calcification [13]. The same author has reviewed 
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this topic after thirty years of research [14–16] describing the MVs as extracellular membrane-invested 
particles of approximately 100 nm (50–200 nm) in diameter. The description highlights that these 
particles are ‘selectively located at sites of initial calcification in cartilage, bone and predentin’ and 
that they are the nucleation centres for the early formation of apatite crystals. In particular, it has been 
reported that these early crystal nuclei are formed within the MVs in close proximity to their bi-
layered phospholipid membrane. Anderson proposed that the MVs biogenesis takes place at ‘polarized 
budding and pinching-off of vesicles from specific regions of the outer plasma membranes of 
differentiating growth plate chondrocytes, osteoblasts, and odontoblasts’. More recently, he reported 
how MVs initiate and promote also a variety of forms of pathological calcification [16]. Polarized 
release of MVs into selected areas of the developing bone matrix prevents the non-random distribution 
of calcification. The early formation of crystal nuclei within the MVs (phase 1) is enhanced by the 
activity of both specific enzymes phosphatases, i.e., alkaline phosphatase, adenosine triphosphatase 
and pyrophosphatase, and by calcium-binding molecules like those of the Annexin family (AnxA1, 
AnxA2, AnxA5 and AnxA6) and like phosphatidylserine (PS); all these macromolecules are localised 
within or near to the MV membrane. The so-called Phase 2 of the biomineralization begins with the 
release of the crystals from the MVs, a process that exposes the preformed hydroxyapatite crystals to 
the extracellular fluid. The extracellular fluid normally contains sufficient Ca2+ and PO43- to support 
continuous crystal growth, with the preformed crystals serving as nuclei (templates) for the formation 
of new crystals by a process defined as homologous mineralization. 
3. Phospholipids and Calcification 
In the first part of the 1970s a series of papers were published that focused on the characterisation 
of the MVs and on their role in initial stages of calcification [17–25]. At the same time, other 
investigators evidenced the role of lipids in calcification [26–31]. In 1976 Vogel wrote that two current 
areas of research on hard tissues were focused upon: (a) acidic lipids associated with the local 
mechanism of calcification, and: (b) the presence of MVs as the loci for initial mineralization. The 
author concluded that “data which show that acidic phospholipids are a component of the vesicle 
membrane provide a common denominator between these two areas” [32]. Studies, then, converged on 
this “lipid-induced calcification” [33] and several phospholipids, in particular PS, were found to play a 
key role (Figure 1). 
It was highlighted that MVs had an overall lipid content higher than either the membrane or cell 
fractions and that they were significantly enriched in serine-phosphoglycerides and cholesterol. 
Despite their different composition, these data supported the view that they were derived from the 
plasma membrane of the cell as earlier conclusions based upon morphological and enzymological 
evidences had already suggested [28]. 
To study the effect of phospholipids on the conversion of amorphous calcium phosphate (ACP) to 
crystalline hydroxyapatite (HA), in vitro experiments were conducted in the presence or absence of PS 
and other phospholipids. In particular, it was demonstrated that PS and other phospholipids possessing 
either anionic or negatively-charged zwitterionic properties were able to bind calcium and that they 
were effective in stabilising ACP. These data were extrapolated to suggest that lipids may play a role 
in the control of physiological mineralization in vivo [29]. 
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Histochemistry studies showed that areas of early mineralisation were intensely stained by lipid-
specific dyes. Later, these lipids were isolated and biochemically characterised as phospholipids. The 
two predominant species were PS and phosphatidyl inositol (PI). Therefore, it was proposed that these 
phospholipids were among the most active nucleation sites of apatite crystal formation in MVs [30]. In 
1976 Wuthier reported that MVs were rich in cholesterol, free fatty acids, sphingomyelin, glycolipids, 
lysophospholipids, and PS, while they were depleted of phosphatidylcholine and ethanolamine. As 
indicated by Anderson, Wuthier also reported that that MVs originate from a budding process of the 
chondrocyte surface membrane. Furthermore, Wuthier highlighted that metabolic studies had indicated 
that the MVs formation is a relatively rapid biochemical process (i.e., less than 6 hours) involving both 
lipid synthesis and degradation [31]. Wu, in 2002, reported on MVs composition showing that 
phosphatidylserine forms complexes that accompany mineral formation, while degradation of other 
membrane phospholipids apparently enables egress of crystalline mineral from the vesicle lumen [34].  
4. A Role for Phosphatidyl-Serine 
Although electron microscopic morphological studies have continued until recently [35–37], the 
bulk of research has focused on a full characterisation of the structures responsible for the early stages 
of calcification. These studies seemed to indicate that this process occurs within the MVs because of a 
more complex assembly of proteins and lipids; some authors have termed these assemblies as 
“nucleators”. The nucleator of bone matrix calcification was described as a protein-phospholipid 
complex where phospholipids were identified as mono and diphosphoinositides and PS [38]. Between 
these two macromolecules, PS was identified as the major phospholipid constituent [39]. Parathyroid 
hormone was found to affect the calcium/PS stimulated phosphorylation of proteins in bone [40] and 
the enrichment of MVs by PS was correlated with the rapid accumulation of Ca2+ in the MV interior [41]. 
Subsequent work gradually led to the identification of the proteins of the lipid-protein complex. A 
quantitatively prevalent group of the MV proteins, the acidic phospholipid-dependent Ca2+-binding 
proteins (APD-CaBP), were found to be immunologically related to the annexin family [42]. 
Calcifiable proteolipids were postulated to enhance apatite deposition by structuring membrane PS 
molecules into a conformation conducive to mineral formation. Annexin and anchorin CII, a protein 
known to bind type II collagen, were closely correlated [43]. A further characterisation highlighted the 
presence of annexin V, a type of ion-selective Ca2+ channel protein that possesses selective collagen 
binding properties [44] and can be defined as a PS-dependent Ca2+-binding protein; it was found to be 
the major protein in the nucleation core [45]. Other investigations have established that calcium uptake 
by MVs depends on the binding of annexin V to collagen type II and type X and that annexin V plays 
a major role in the MV-initiated cartilage calcification as a collagen-regulated calcium channel [46]. 
In 1997, while studying the process of calcification in liposomes (artificial membranous lipid 
vesicles), Kirsch speculated that since the lipid composition of matrix vesicles is rich in PS, it may 
regulate annexin V function. In particular, a significant Ca2+ influx in presence of annexin V occurred 
only in liposomes containing a high PS content. His studies indicate that PS-rich bilayers induce the 
formation of a hexameric annexin V, possibly leading to a Ca2+-dependent insertion of annexin V into 
the phospholipid bilayer and to the establishment of annexin V-mediated Ca2+ influx into MVs or 
liposomes [47]. 
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Figure 1. A “skeleton” model of 1-palmitoyl-2-oleoyl-SN-glycero-3-phospho-L-serine 
built by the first author in 1981. The carbon tail on the right is shown partially. 
 
To emphasise the important role played by MVs in biomineralization, Genge, Wu and Wuthier have 
recently stated that MVs “are involved in de novo mineral formation by nearly all vertebrate tissues”. 
These authors have summarised the biomineralization potential of these structures in the composition 
of their nucleation core that they reported to be composed of three principal interacting constituents: 
(i) the amorphous calcium phosphate (ACP), (ii) calcium-phosphate-lipid complexes (CPLX) formed 
by ACP partially combined with PS and (iii) annexin A5 (AnxA5). AnxA5 synergistically activates 
PS-CPLX transforming it from a very weak nucleator of mineral formation into a potent nucleation 
site [48–51]. 
Other proteins than the annexin family can bind to PS such as the milk fat globule epidermal growth 
factor 8 (MFG-E8) [52–55]; a product of the growth arrest-specific gene 6 (Gas6) [55–58]; the 
developmental endothelial locus-1 (Del-1) [59]; the serum-derived protein S [60–61]; the T cell 
immunoglobulin mucin protein 4 (Tim-4) [62–66]. Although, there are no experimental evidence of 
possible implications of these proteins in matrix-vesicles-induced mineralization, one can not exclude 
that they may be implicated in cell-induced and/or extracellular-induced mineralization. 
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5. Technological Application of Artificial MVs 
It is widely accepted that the integration of artificial implants into the treated bone depends on the 
ability of the material to support the early apposition of newly synthesized bone at the implant surface. 
In 1995, Braun placed titanium implants in the right tibias of rats following ablation of the marrow 
showing that MVs and PS content as well as alkaline phosphatase and phospholipase A2 activity were 
increased showing a peak after 6 days. However, the same study highlighted that these levels were 
lower than those observed in bone healing in absence of the implant [67]. 
In 1998, Taylor synthesized a PS-amorphous calcium phosphate complex as a model of the matrix 
vesicle system [68]. In 2000, Sela studied osteogenesis around implants and observed that this process 
depended on the migration of osteoprogenitor cells to the implant site as well as to their ability to 
synthesise and secrete a mineralising extracellular matrix. The study concluded that as osteogenesis 
around implants is similar to the new bone formation, the mechanism by which the cells calcify their 
matrix involves MVs in a process of "primary mineralization" [69]. Parallel studies proposed 
liposomes as model structures for biological calcification processes and showed that these structures 
were able to promote calcification and accelerate the formation of bone-like tissue [70]. 
In 2002, Camolezi and co-workers standardized a method for an alkaline phosphatase-liposome 
system to mimic matrix vesicles. The 395 nm diameter of the alkaline phosphatase-liposome system 
was relatively homogeneous and stable when stored at 4 degrees Celsius and by this system the kinetic 
behavior of the incorporated enzyme was examined in vitro [71]. 
 
5.1. Calcium-binding phospholipids as coating molecules of medical implants: Early evidences of their 
osteointegrative potential 
 
In vitro coating of implantable materials was experienced to evaluate the effect of different 
phospholipid coatings on osteoblast responses. In 1998, the team at the School of Pharmacy and 
Biomolecular Sciences, University of Brighton, UK, started a collaborative project (acronym: 
Lipostin) sponsored by the European Commission that involved partners from different European 
countries. This project soon led to the developing and intellectual property protection of a novel 
method of coating of implants with calcium-binding phospholipids such as PS and PI (A.W. Lloyd, M. 
Santin, W.G. Love, S.P. Denyer, W. Rhys-Williams. Biomedical Implants, 2000, PCT/GB00/03290 
[72]). Different formulations were optimised that were able to form a 3D hydrogel interpenetrating the 
porous surface of medical-grade titanium implants and to induce a rapid mineralization of their surface 
upon incubation in simulated body fluids (SBFs). 
Later, by a similar approach, Satsangi tested commercially available phospholipids 
(phosphatidylcholine, PS and PI) converting them to their Ca-PL-PO(4) and coating commercially 
pure titanium grade 2 disks [73]. Using uncoated Ti surfaces as controls, cell responses to 
phospholipid-coated surfaces were evaluated using the American Type Culture Collection CRL-1486 
human embryonic palatal mesenchymal cells, an osteoblast precursor cell line, over a 14-day period. 
Titanium surfaces coated with PS exhibited enhanced protein synthesis and alkaline phosphatase 
specific activity compared to other phospholipids and uncoated surfaces [73]. The, polar head group of 
phospholipids in coated surfaces was observed to have an influence on the calcium deposition as well 
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as the osteoblast differentiation. Among the phospholipids evaluated, PS exhibited the strongest 
calcium deposition and more enhanced alkaline phosphatase specific activity [74]. 
Susin and co-workers recently followed a similar approach with phosphorylcholine (PC); they 
coated titanium implants and analyzed in vivo in the rabbit the biomechanical (removal torque) and 
histomorphometrical results. They did not find any significant differences in bone density with control 
implants, nevertheless they concluded that PC coating technology appears to be a viable candidate 
delivery system for agents in support of local bone formation at endosseous implant surfaces [75]. 
Following protection of the intellectual properties, a series of papers were published by the team at 
the University of Brighton that showed the full potential of this technology both in vitro and in vivo. 
Santin et al. showed that in PS-based coatings, deposited on titanium coupons by dip-coating, upon 
dehydration in a simulated body fluid lead phospholipids to quickly crosslink by calcium ions and re-
arranged into a three-dimensional matrix able to induce rapid formation of a calcium phosphate 
mineral phase. In the attempt to closely mimic the cell membrane composition, heterogeneous 
formulations based on the mixing of anionic phospholipids (either PS or PI) with phosphatidylcholine 
and cholesterol were synthesized. However, homogeneous PS coating was a more effective 
calcification environment than the heterogeneous formulations [72]. Other studies suggested that in 
addition to improving the nucleation process for new bone formation, coating titanium with 
phospholipids may reduce the inflammatory response, which was shown to vary depending on the 
formulation employed. When compared to uncoated titanium and HA-coated implant, PS significantly 
reduced the adhesion of the inflammatory cells, i.e., the monocytes/macrophages [76]. It has been 
speculated that this lack of adhesion is caused by the natural role played by PS during the phagocytosis 
of apoptotic cells. Indeed, during the programmed cell death, the apoptosis, the PS molecules of the 
plasmalemma bilayer flip from the cytoplasm side of the membrane towards the cell surface. This 
presentation of PS molecules to the cell surface is recognized by the macrophages as a signal for the 
clearance of the dead cells by phagocytosis. In the case of PS-coated implants, the relatively large size 
of the surface does not allow the macrophages to phagocyse the foreign body; this fact produces an 
actual inhibition of macrofages adhesion and activation, thus provoking an eventual anti-inflamatory 
action of PS coating. The biocompatibility of these phospholipid-based coatings, in combination with 
their ability to initiate rapid mineralisation, showed that these coating could promote bone cell 
interactions in vitro and, as a consequence, had a promising potential to support implant 
osteointegration in vivo [77]. 
5.2. In vivo response to phosphatidyl-serine coating 
The promising features showed by the in vitro experiments on titanium implants coated with 
calcium-binding phospholipids prompted the validation of their osteointegrative potential in vivo. The 
aim of the in vivo study was to assess the ability of these biomaterials to offer an alternative to 
traditional osteointegrative coatings such as those based on bioactive ceramics. Indeed, bioactive 
ceramics such as HA are employed as coatings to enhance the fixation of metallic devices; they act as 
a scaffold to enhance bone formation on their surface. The osteointegrative potential of synthetic HA 
(the most widely used bioactive ceramic material in surgery) is linked to its chemical nature which is 
very similar to that of the bone mineral phase thus providing an optimal substrate for the growth of the 
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osteoblasts [78]. The discovery that osteoblasts can grow easily on artificial HA, both as a bulk 
material and as a plasma-spray coating, improved significantly the possibility of obtaining a favorable 
response to the implantation of devices that were loaded or coated with HA. Not only are osteoblasts 
found growing on HA, but osteoclasts also are able to resorb it thus involving the biomaterial in the 
physiological bone turnover [79]. For these reasons, HA has rightly been considered as a biomimetic 
biomaterial [80] and coating an implant with HA has become an effective system to mask the foreign 
body nature of the underlying implant material. Nevertheless, drawbacks are associated with the use of 
HA. In particular, highly crystalline HA (crystallinity of 85%, according to the method of Tudor et al. 
[81]) renders the coating brittle under biomechanical stresses and prone to a slow degradation into 
particles [79], while lower crystalline coatings is prone to a relatively rapid degradation in body  
fluids [82]. 
Therefore, PS-based coatings seemed to offer an opportunity to generate a rapidly mineralizing 
substrate at the bone/implant interface. To prove this, an in vivo study using a well-established rabbit 
femoral model was adopted. The osteointegration of porous titanium implants coated with either PS or 
phosphatidyl choline/PS/chloresterol formulation was compared by the use of high-magnification 
back-scattering scanning electron microscopy (BSEM) to uncoated titanium as well as to conventional 
plasma spray HA coatings. Results showed that PS-based coatings were gradually resorbed while 
being able to promote the apposition of new bone to the metal surface at level higher than bare 
titanium [83]. 
In particular, after four weeks implantation, the control Ti shows bone trabeculae growing towards 
and around the implant. High magnification of the bone/implant interface, however, showed that the 
new bone did not establish a direct contact with the material surface. At eight and 26 weeks the 
titanium foam allowed the penetration of a healthy and remodelling trabecular bone throughout its 
porosity, but still showed areas of incomplete apposition of tissue in several specimens when analysed 
at high magnification. In the case of the PS-coated implants, the low magnification analysis after four 
weeks of implantation shows a bone formation with trabeculae growing towards the surface of the 
implant. The newly-formed bone was not adjacent to the implant surface when analysed at high 
magnification. After eight weeks, however, the newly-formed trabecular bone in-growth had invaded 
almost completely the porous implant establishing a direct contact with its surface in most of the areas 
analysed (Figure 2). 
Tissue morphology at the implant surface was observed to be normal after 26 weeks when the 
invasion of the tissue was still readily visible and its apposition to the implant surface consolidated 
(Figure 3). 
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Figure 2. BSEM transverse section of a PS-coated titanium foam cylinder after eight 
weeks of implantation into a rabbit femur (magnification 15×). 
 
 
Figure 3. BSEM transverse section of a PS-coated titanium foam cylinder after 26 weeks 
of implantation into a rabbit femur (magnification 250×). 
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The relatively slow degradation of the phospholipid coatings was obviously not able to match the 
fast rate of apposition of bone to the HA surface. However, taken into account the clinical problem 
associated to the delamination of HA coatings from the surface of metal implants, the ability of the 
phospholipid coatings to mediate a final tight apposition of bone to the metal implant is likely to offer 
a long-term clinical benefit. These promising results can be explained by the data collected in vitro 
showing the fast mineralization of the phospholipid coatings and their good substrate properties for 
osteoblast adhesion [72,76–77]. It can be speculated that the mineralization potential and resorption of 
calcium binding-phospholipids can gradually drive the in-growth of new bone tissue towards the 
implant surface allowing a final, intimate contact between the mineral phase and the metal. 
Furthermore, the lack of adverse fibrous reaction confirmed the ability of the phospholipid coatings to 
control the inflammatory response to the implant. 
7. Conclusions 
During a period of about thirty years PS has been recognized as one important molecule involved in 
the mineralization process in bone formation. When exploited as a possible functionalisation molecule 
for artificial implants, this new type of biomimetic (matrix vesicle-like) biomaterial was able to 
promote the osteointegration of titanium implants. PS coating, uniquely re-arranged into 3-D porous 
gels when immersed in buffer simulating the body fluid composition showing their potential to prevent 
the formation of non-mineralised tissue in vivo. These phospholipid-based coatings have also shown 
the ability of affect other important component of the bone repair process, the osteoblast and the 
inflammatory cells. Osteoblast adhesion and proliferation was clearly enhanced on the surface of 
titanium implant coated with PS, while inflammatory cell adhesion was inhibited. Therefore, PS 
coatings seem to fulfil all the main characteristics required to the functionalisation of medical implants 
where osteointegration is required. However, this technology based on calcium-binding phospholipid 
can also be exploited to produce tissue engineering scaffolds. Recently a paper has been published 
about a composite scaffold for potential use in bone tissue engineering, to examine the in vitro reponse 
elicited in human mesenchymal stem cells (hMSCs); this novel biomimetic scaffold is based on a mix 
of bioactive glass–collagen–hyaluronic acid-PS [84]. 
These encouraging research projects prompt the use of this technology in clinical applications 
where bone repair needs to be pursued by the means of highly performing, safe and commercially 
sustainable biomaterials. 
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